While counterfeit medicines are often viewed as a modern, high-tech threat driven by e-commerce and complex global supply chains, deception in medicine is one of humanity’s oldest crimes.
As early as the first century, Greek physician Dioscorides has warned of fake remedies in Materia Medica.
In Malaysia, the persistence of counterfeit and unregistered medicines reflects more than weak enforcement. It is sustained by cultural habits, consumer psychology, and legal blind spots that continue to create fertile ground for exploitation.
Stigma, Self-Diagnosis, And The “Quick Fix” Culture
A major driver of Malaysia’s fake medicine trade is the widespread culture of self-diagnosis and the pursuit of cheap, immediate solutions outside legitimate healthcare systems. Counterfeiters exploit this vulnerability with precision.
Men suffering from erectile dysfunction (ED), for example, are prime targets because stigma often discourages them from seeking professional medical help. Many instead turn to anonymous online sellers, street vendors, or unlicensed pharmacies.
Women, meanwhile, are frequently targeted through counterfeit beauty products, slimming supplements, and cosmetic medicines that promise rapid physical transformation, capitalising on social pressures surrounding appearance.
In both cases, counterfeiters do not merely sell products, they manipulate shame, insecurity, and desperation.
The “Broken Windows” Approach And Its Limits
Malaysia’s Pharmacy Enforcement Division (PED) has adopted a “broken windows” strategy: aggressively targeting small retailers, night market sellers, and street peddlers to prevent larger criminal networks from flourishing.
While this strategy may disrupt visible distribution points, it risks overlooking a deeper institutional problem: medicine counterfeiting is still too often treated as a commercial offence rather than a public health crime.
This professional blind spot is evident when counterfeit medicine cases are approached primarily through trademark infringement or regulatory breaches, rather than through the lens of human harm. Unlike counterfeit handbags or luxury goods, counterfeit medicines can kill.
Even minor packaging similarities or misleading labels can result in fatal consequences. Yet, sentencing often reflects economic loss more than bodily risk.
The Definition Loophole And Malaysia’s Weak Deterrence Problem
A critical legal flaw lies in Malaysia’s tendency to conflate counterfeit medicines with unregistered medicines, despite the two representing fundamentally different threats.
Unregistered medicines are generally regulatory violations involving market authorisation failures. Counterfeit medicines, by contrast, are deliberate acts of fraud involving deception about identity, origin, or composition.
However, neither the Sale of Drugs Act (SODA) 1952 nor the Control of Drugs and Cosmetics Regulations (CDCR) 1984 explicitly defines “unregistered medicine,” “counterfeit medicine,” or any other equivalent term of similar regulatory significance.
This ambiguity allows counterfeit medicines to be subsumed into broader regulatory categories, diluting the criminal nature of the offence.
The result is a troubling deterrence gap: both counterfeit and unregistered medicines are often prosecuted under Section 12 of SODA 1952, a general penalty provision that lacks mandatory minimum penalties.
When deliberate pharmaceutical fraud is punished under laws designed for broad regulatory non-compliance, the legal response risks understating the seriousness of the crime.
The Expert Gap: When Enforcement Fails In Court
Malaysia’s challenge is not only legislative but operational. Complex pharmaceutical crime increasingly requires specialised investigative skills, digital forensic competence, and prosecutorial precision.
Yet, enforcement officers and prosecutors may not always possess the technical expertise necessary to dismantle sophisticated counterfeit networks.
Poor documentation of evidence, breaks in the chain of evidence, and procedural failures can collapse otherwise strong cases, allowing larger criminal actors to evade accountability while smaller distributors are prosecuted.
This creates a dangerous imbalance: the visible seller is punished, while the system’s architects remain untouched.
A Public Health Crime, Not Just A Regulatory Issue
Malaysia’s fake medicine problem cannot be solved solely by increasing raids or tightening online sales controls. It requires a deeper shift in legal philosophy and public consciousness.
Counterfeit medicines must no longer be viewed through the narrow lens of intellectual property infringement or simple regulatory non-compliance; they are products of intentional crime and deliberate deception that should be defined and punished according to the severity of the harm they pose to human health.
Until Malaysia’s legal framework clearly distinguishes counterfeit medicines from unregistered products, imposes penalties proportionate to deliberate pharmaceutical deception, and addresses the social stigma that drives vulnerable consumers into shadow markets, seizures worth millions will remain reactive symptoms rather than preventive cures.
Fake medicines have survived for centuries because human vulnerability has remained constant. Malaysia’s true challenge is not simply defeating counterfeiters, but overcoming the ancient habits that allow them to thrive.
Saiman Raj Aruldas is an independent researcher and a graduate of Multimedia University, holding a Master of Laws (LLM) specialising in pharmaceutical law.
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.